Induced pluripotent stem cells (iPS cells) can be made by reprogramming mature adult cells back into an embryonic-like state. Derived from skin or blood cells, iPS cells are not controversial, because they are made from adult cells. As pluripotent stem cells, they can give rise to all of the tissues that form the human body. [Read more…]
Applied StemCell Demonstrates Efficient Knock-In of a 50 kb DNA Construct into Human iPSCs Using TARGATT™ Technology
MILPITAS, Calif., Nov. 11, 2025 – Applied StemCell, Inc. (ASC), today announced the successful knock-in of a 50 kilobase (kb) multifunctional DNA insert into human induced pluripotent stem cells (iPSCs) using its proprietary TARGATT™ technology. The achievement establishes a new benchmark for the size and complexity of genetic payloads that can be efficiently and site-specifically integrated into the human genome. [Read more…]
Interview with Dr. Nianwei Lin, Co-Founder and President of iXCells Biotechnologies
Founded in 2014 and headquartered in San Diego, CA, iXCells Biotechnologies is a cell biology and cell technology company specializing in pre-clinical drug discovery solutions. iXCells provides primary cells and iPSC derived cells, custom iPSC services, and functional bioassay development and execution, among other products and services.
In this interview with Nianwei Lin, Co-Founder and President of iXCells Biotechnologies, we discuss the company’s product pipeline, innovative drug discovery solutions, CRO services, and its future goals. [Read more…]
The Future of Allogeneic Cell Therapy is Off-the-Shelf and iPSC-Based – An Interview with Cellistic’s Founder and CTO, Stefan Braam, PhD
In the rapidly evolving field of cell therapy, scalability and accessibility remain two of the biggest challenges for widespread patient impact. Cellistic, a leading company that is pioneering allogeneic cell therapy solutions, is tackling these obstacles head-on with its novel induced pluripotent stem cell (iPSC) technologies. In this interview, Stefan Braam, PhD, Founder & Chief Technical Officer of Cellistic, shares insights into the company’s journey, its innovative platforms—including Pulse™, Echo™, and the newly introduced Allo Chassis™—and how these advancements are poised to redefine cell therapy development as we known it.
With a clear focus on efficiency, cost reduction, and clinical translation, Cellistic is at the forefront of making off-the-shelf, immune-cloaked cell therapies a reality. Enjoy! [Read more…]
Human Induced Pluripotent Stem Cell (iPSC) Derived Tissues – Present & Future Outlook
In this article, the present and future outlook for human iPSC-derived tissues is explored. Induced pluripotent stem cells (iPSCs) are differentiated cells that are reprogrammed into a pluripotent state, allowing a wide range of cell and tissue types to be derived from them.
Key findings include:
- iPSC technology is moving from a boutique phenomenon to industrialized cellular models.
- Increasing recognition by industry and regulatory bodies for detecting a variety of toxicities.
- Emerging utility for predicting cardio and neuro-related oncology adverse effects.
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 79
- Next Page »